Project Grant HT94252510935
- This federal Project Grant award, titled "UNDERSTANDING HOW MELANOMA-COGNATE T-CELL HELP ENHANCES SURVIVAL WITH MELANOMA VACCINES," was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $858,608 award will support advanced biomedical research at the University of Virginia (UVA) focused on transforming healthcare for military service members, veterans, and the public through innovative cancer research. The 3-year...
- This Project Grant award, valued at $638,260.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Rector & Visitors of the University of Virginia (UVA). The funding supports research to investigate "LINKING GENETIC, METABOLIC, AND MICROENVIRONMENTAL PREDICTORS OF MELANOMA METASTATIC COLONIZATION" over the project period of September 1, 2025 to August 31, 2027. UVA, a prominent public research university,...
- The Defense Health Agency awarded a $1,592,860 Project Grant to the Rector & Visitors of the University of Virginia (UVA) on January 1, 2025 under the Military Medical Research and Development program (CFDA 12.420). The grant will support UVA's research to develop ultrasensitive proteomics techniques for predicting and assessing treatment efficacy for type 1 diabetes. This work aims to transform healthcare for military service members and the broader public by advancing innovative biomedical...
- The University of Virginia received a $921,351 project grant award on September 30, 2023 from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to support research on "APPROACHES TO ENHANCE VACCINE-INDUCED TUMOR-INFILTRATING LYMPHOCYTES (VITILS) IN MELANOMA". This multi-year grant, scheduled for completion on September 29, 2026, aims to advance biomedical research that can transform healthcare for Service Members and the American public. The...
- The Department of Defense's Defense Health Agency awarded a $2,728,777 Project Grant to the Rector & Visitors of the University of Virginia (UVA) under the Military Medical Research and Development (CFDA 12.420) program. The grant is for a research project titled "NEUROACTIVE STEROID BIOSYNTHESIS AND DYNAMIC GABAA RECEPTOR RECONFIGURATION IN POSTPARTUM DEPRESSION" with a performance period from May 1, 2025 to April 30, 2029. The project aims to conduct advanced biomedical...
- The Defense Health Agency awarded a $847,875 Project Grant to the Rector & Visitors of the University of Virginia (UVA) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Targeting Schwann Cell-Tumor Microenvironment Interactions in Neurofibroma Development," supports advanced biomedical research to transform healthcare for military service members, veterans, and the public. The research project at UVA aims to investigate the cellular...
- This $693,642 federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research at the University of Virginia to enhance vaccine-induced tumor-infiltrating lymphocytes (VITILS) in melanoma. The 3-year research project aims to develop innovative approaches to boost the effectiveness of cancer immunotherapies by improving the ability of T cells to infiltrate and attack melanoma tumors. Key deliverables will include...
- The U.S. Defense Health Agency awarded a $5,540,949 Project Grant to the Rector & Visitors of the University of Virginia (UVA) to conduct research on focused ultrasound interventions for noninvasive precision therapy in primary and metastatic breast cancers. This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military service members, veterans, and the broader public. The...
- The Project Grant award of $3,208,546.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports the expansion of the Generalized Blast Exposure Value Tool to determine cumulative blast exposure thresholds in military populations. The award was granted to the Rector & Visitors of the University of Virginia, a prominent public research university, on May 15, 2025, with a completion date of May 14, 2029. The goal of this research...
- This $646,252 Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) supports research to uncover cell intrinsic and extrinsic factors governing melanoma dormancy at single-cell resolution. The primary awardee, Trustees of Boston University, will conduct this advanced biomedical research. The University of Virginia will provide academic and technical resources, including experiments generating and validating...
The Rector & Visitors of the University of Virginia (UVA) was awarded a $1,528,632 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on August 15, 2025, supports research to understand how melanoma-cognate T-cell help enhances survival with melanoma vaccines. The research, to be conducted in Charlottesville, VA, aims to transform healthcare for military service members, veterans, and the public by advancing innovative medical solutions to address critical health challenges relevant to the military. The Project Grant, with a performance period ending on August 14, 2028, is part of the Defense Health Agency's comprehensive portfolio of basic, applied, and translational medical research initiatives across multiple domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.5m | 8/7/25 |